Donanemab Side Effects

Medically reviewed by Drugs.com. Last updated on Sep 10, 2024.

Applies to donanemab: intravenous solution.

Important warnings This medicine can cause some serious health issues

Donanemab can cause temporary swelling or bleeding in the brain that usually clears up with time.

This may cause no symptoms but can be serious.

Call your doctor if you have headaches, dizziness, nausea, confusion, trouble walking, seizures, or vision changes.

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have chills, a headache, chest tightness, back pain, trouble breathing, skin irritation, or swelling in your face.

Donanemab can cause temporary swelling or bleeding in the brain, especially if you use medication to prevent blood clots.

Call your doctor if you have:

• dizziness, confusion, headache;

• vision changes;

• seizures;

• vomiting, nausea; or

• trouble walking.

Common side effects may include:

• ARIA with symptoms, or with signs that appear on an MRI; or

• headache.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For healthcare professionals

Applies to donanemab: intravenous solution.

General adverse events

The most frequently reported side effects included amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H) microhemorrhage, ARIA-H superficial siderosis, ARIA-edema (ARIA-E), and headache. The most common side effect resulting in discontinuation was infusion-related reaction.^[Ref]

Gastrointestinal

• Uncommon (0.1% to 1%): Intestinal obstruction, intestinal perforation^[Ref]

Hypersensitivity

• Common (1% to 10%): Hypersensitivity reactions (including anaphylaxis)^[Ref]

Immunologic

• Very common (10% or more): Developed antidrug antibodies (87%), developed neutralizing antibodies (87%)^[Ref]

About 10% of patients who developed antidrug antibodies while taking this drug reported infusion-related reactions.^[Ref]

Nervous system

• Very common (10% or more): ARIA-H microhemorrhage (25%), ARIA-E (24%), ARIA-H superficial siderosis (15%), headache (13%)^[Ref]

Patients have had both microhemorrhage and superficial siderosis.^[Ref]

Other

• Common (1% to 10%): Infusion-related reactions^[Ref]

Frequently asked questions

• How quickly does Kisunla start working?

Further information

Donanemab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer